Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Alfa Aesar Acquires Biomedical Technologies, Inc.

Published: Thursday, September 19, 2013
Last Updated: Thursday, September 19, 2013
Bookmark and Share
Alfa Aesar to leverage BTI’s manufacturing capabilities to enhance its product offering.

Alfa Aesar has announced that it has completed the purchase of Biomedical Technologies, Inc. (BTI) of Stoughton, Massachusetts.

BTI has been manufacturing life science research products for more than 30 years, with a commitment to its customers of technology, quality and value.

Its product line includes specialty proteins, cell culture additives and highly specific immunoassay tools, which Alfa Aesar will continue to build upon as it expands its portfolio of unique biochemical products for the researcher.

Commenting on the transaction, Julie Butterfield, General Manager of Alfa Aesar said: “Alfa Aesar is already known for providing researchers access to unparalleled expertise and supply of a wide variety of inorganic and organic chemicals used in both academia and industry. For our customers in the life sciences, we are committed to enhancing our offer in the biochemical arena through a selection of methodically chosen products that complement our current portfolio and build on our core competencies. The acquisition of BTI brings protein research and characterization, all types of profiling tools, and certain separation technologies and provides opportunities for Alfa Aesar to leverage BTI’s manufacturing capabilities to enhance its overall product offering.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Cambridge, Office for Alfa Aesar
New and exciting chapter in Alfa Aesar’s UK history.
Tuesday, June 02, 2015
Biomedical Technologies Enhances Lipoprotein Manufacturing Capabilities
Biomedical Technologies (BT) has doubled its ultracentrifuge capacity, enhancing manufacturing capabilities for custom products in response to market demand.
Monday, June 01, 2015
Alfa Aesar Introduces New “GET” Channel Partner Program
An excellent opportunity for new partners to emerge for Alfa Aesar.
Thursday, April 24, 2014
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!